Shionogi Acquires Global Rights to AQNEURSA for Rare Disease Treatment

Shionogi announced it had signed an agreement to acquire IntraBio Inc., a biopharmaceutical company focused on rare neurodegenerative diseases. The purchase price is set at $2 billion for all outstanding shares of IntraBio. The acquisition grants Shionogi global rights, including intellectual property and commercial rights, to AQNEURSA and related compounds.

AQNEURSA is approved in the United States and Europe for neurological manifestations of Niemann-Pick disease type C, a rare lysosomal disorder. The deal allows Shionogi to expand its rare disease operations by integrating IntraBio's assets into its existing infrastructure.